10 Overlooked Healthcare Stocks to Invest in

6. CorMedix Inc. (NASDAQ:CRMD)

Number of Hedge Fund Holders: 29 

CorMedix Inc. (NASDAQ:CRMD) is a biopharmaceutical company focused on therapies to prevent and treat life-threatening diseases, with DefenCath, an antimicrobial catheter lock for dialysis patients, as its lead commercial product.

In August 2025, CorMedix Inc. (NASDAQ:CRMD) announced the acquisition of Melinta Therapeutics, a commercial-stage company with seven marketed hospital- and clinic-focused infectious disease products, including REZZAYO™ for candidemia and invasive candidiasis. The acquisition, expected to close by September 1, will diversify CRMD’s portfolio, expand its acute hospital care presence, and enhance R&D and commercial capabilities. The combined company is projected to generate $305–$335 million in 2025 revenue, with annual synergies of $35–$45 million, and is expected to be accretive to earnings with double-digit EPS growth in 2026. This strategic move also highlights how CRMD, often categorized among overlooked stocks, is positioning itself for broader recognition in the healthcare space.

CorMedix Inc. (NASDAQ:CRMD) continues to see strong growth in DefenCath sales, supporting its market position. The corporation faces some legal challenges from shareholder lawsuits alleging misleading statements, contributing to stock volatility.